We use necessary cookies to make our website work. We also use optional statistical, functional and marketing cookies that you can choose to decline in your preference setting. For more information about the use of cookies or our use of data, see our Cookies notice or Privacy notice

Cookies settings I agree I refuse

Cookies information

Our site uses tools, such as cookies, to analyze and improve your experience. You can unsubscribe below:


We use tools, such as Google Analytics, to track web traffic and verify the effectiveness of our site.


Cookies required for essential services and features such as login forms, shopping cart integration and access control. Without them, our website cannot function properly and we cannot provide any services. Deactivation is not available.

These settings will be kept for 24h


Clinical trials

  • Ir-CPI

    This Phase IIa study aims to evaluate the safety, tolerability and the effects of Ixodes Ricinus-Contact Phase Inhibitor (Ir-CPI) in adult patients with spontaneous intracerebral hemorrhage (BIRCH trial)

    • ClinicalTrials.gov Trial Identifier NCT05970224
    • Recruitment status Ongoing
    • Official Title A Phase IIa, Randomized, Open-label, Proof-of-Concept Study to Evaluate Safety, Tolerability and Efficacy of Ir-CPI in Patients With Spontaneous Intracerebral Haemorrhage
    • Study Start Date July 27, 2023
    • Primary Completion Date (Estimated) August, 2025



  • Ir-CPI

    This First-In-Human (Phase I) study is a double blind, placebo controlled, single ascending dose trial performed in healthy adult male volunteers with Ir-CPI.

    • ClinicalTrials.gov Trial Identifier NCT04653766
    • Recruitment Status Completed
    • Study Start Date September 12, 2019
    • Primary Completion Date July 18, 2020
    • Study Completion Date January 4, 2023
    • The primary objectives of the study were to evaluate the safety and tolerability of Ir-CPI.
    • Secondary study objectives included pharmacokinetic (PK) and pharmacodynamic (PD) assessment of Ir-CPI, i.e. the effect on prolongation of the aPTT coagulation parameter and on the inhibition of FXI and FXII activity.
    • Thirty-two (32) healthy adult male volunteers were enrolled in this trial with a ratio 6-active and 2-placebo per dose level.
    • A total of 4 dose levels of Ir-CPI ranging from 1.5 mg/kg up to 9 mg/kg were tested and administered intravenously for a 6-h period of infusion.

Study Design

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment